Anti-TB treatment was offered at least 12 months for the preventive anti-TB group.

And there is no serious adverse reaction during preventive anti-TB treatment.

Results: No active TB occurred in anti-TB treatment group.

The project is restricted to anti-TB treatments suitable for people whose TB is not resistant to standard therapies.

Systemic symptoms decreased during corticosteroid treatment, but abscesses only disappeared 8 months after the start of the anti-TB treatment.

Gene expression levels were also measured six months after anti-TB treatment (ATT) and follow-up in 38 TB patients.

First, diagnostic screening is needed in patients who have undiagnosed active TB so that timely anti-TB treatment can be started.

We retrospectively reviewed the clinical records, results of bacteriological examinations, and radiographs of the included patients and the response to anti-TB treatment.

The significant independent risk factors for mortality during anti-TB treatment were advancing age, male sex, sputum smear positivity, and the presence of a comorbidity.

These findings provide a basis for exploring the potential use of adjunctive immune modulation with PDE4 inhibitors to enhance the efficacy of existing anti-TB treatment.

This problem has partly been attributable to the existence of nonreplicating M. tuberculosis "persisters" that are difficult to kill using conventional anti-TB treatments.

Conclusion: For high-risk population of active TB, glucocorticoid therapy plus 1 or 2 preventive anti-TB treatment drugs may prevent its occurrence.

Methods: We studied 887 sputum smear positive PTB patients, between 18 and 65 years of age receiving standard 8 months anti-TB treatment.